LeonaBio, Inc. Common Stock (LONA) is a publicly traded the market company. As of July 27, 2026, LONA trades at $7.35 with a market cap of $69.42M and a P/E ratio of 0.00. LONA moved +0.00% today. Year to date, LONA is +0.00%; over the trailing twelve months it is flat. Its 52-week range spans $4.21 to $14.21. Analyst consensus is buy with an average price target of $18.00. Rallies surfaces LONA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
LeonaBio to Present ATH-1105 Trial Design June 3 in Boston; Oncology Panel June 24 in San Diego: LeonaBio will present its lead candidate ATH-1105 at the 5th Annual ALS Drug Development Summit in Boston on June 3, detailing strategic trial design and biomarker integration. The company will also discuss oncology trial alignment and investment in a June 24 panel at the BIO International Convention in San Diego.
| Metric | Value |
|---|---|
| Price | $7.35 |
| Market Cap | $69.42M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $14.21 |
| 52-Week Low | $4.21 |
| Volume | 5.66K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
2 analysts cover LONA: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $18.00.